Media Type: Presentations

Key takeaways Symptomatic management is an essential component of Multiple Sclerosis (MS) care, addressing spasticity, ataxia, mobility impairment, tremor, sensory disturbances, and pain to improve daily functioning and quality of life. Spasticity affects approximately 60% of people with MS and can significantly impair mobility, sleep, and overall quality of life. Spasticity management requires a combination of pharmacological and non-pharmacological approaches, including rehabilitation, stretching, oral antispastic agents, nabiximols, botulinum toxin injections, and intrathecal...

Key takeaways Generics and biosimilars are increasingly relevant in Multiple Sclerosis (MS) as healthcare systems seek cost containment without compromising clinical outcomes. Biosimilars are not identical copies, but are rigorously evaluated to demonstrate high similarity to reference biologics in structure, efficacy, safety, and immunogenicity through the EMA/FDA “totality of evidence” framework. Clinical trials and real-world evidence consistently show comparable efficacy and safety between originator biologics and biosimilars used in MS, including interferon beta, rituximab...